NCT07874984Not yet recruitingPhase 2
SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer
A Phase 2 Study of SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
This study is an open, multicenter, phase 2 clinical trial of SPGL008 in combination with SSGJ-706 ± chemotherapy for the treatment of advanced non-small cell lung cancer. The objective is to evaluate the safety and efficacy of SPGL008 combined with SSGJ-706 in participants with driver gene-negative advanced non-small cell lung cancer.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 220 (estimated)
- First submitted
- 20 Sept 2026
- Start date
- Nov 2026
- Primary completion date
- Nov 2027
- Lead sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Diseases
- Lung cancer
- NCT number
- NCT07874984
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 220
- From Nov 2026 to the primary completion date, Nov 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \>1 (National Cancer Institute Common terminology Criteria
Other illness
- Known allergies, hypersensitivity, or intolerance to SSGJ-706/SPGL008 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Other
- Known positive driver genes
- Pregnant or breast-feeding woman.
Who the study is looking for
- Males and/or females over age 18-75
- Histologically and/or cytologically documented local advanced or metastatic NSCLC .
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Expected survival \>=3 months.
- Adequate organ or bone marrow function.
- Signed informed consent form.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.